Form D · Biotechnology
Septerna, Inc.
South San Francisco, CA · CIK 0001984086
Offering snapshot reported Jul 13, 2023 · SEC filing
- Reported sold
- $73.5M Offering amount: $150M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 28, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 13, 2023 | Initial | $73,499,988 | No comparison | 30 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-486777
Source: Form D, filed Jul 13, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Abraham Bassan | Director |
| Elizabeth Bhatt | Executive |
| Alan Ezekowitz | Director |
| Jeffrey Finer | Director, Executive |
| Samira Shaikhly | Executive |
| Jake Simson | Director |
| Jeffrey Tong | Director |
| Ran Xiao | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
250 East Grand Avenue, Suite 65
South San Francisco, CA, 94080
South San Francisco, CA, 94080